Dobbs V. Wyeth: Are We There Yet, And At What Cost?

Law360, New York (November 15, 2012, 3:10 PM EST) -- The battle over preemption of state law failure-to-warn claims involving pharmaceuticals bearing U.S. Food and Drug Administration-approved warnings has been waged for more than a decade. It continues with efforts to secure preemption of state law claims involving the prescription anti-depressant Effexor in Dobbs v. Wyeth.

The United States Supreme Court’s groundbreaking 2001 ruling in Buckman Co. v. Plaintiffs’ Legal Committee, holding that state law fraud-on-the-FDA claims conflict with federal law and therefore are impliedly preempted, fostered hope among members of the defense bar that preemption...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.